Comparison of the effectiveness and safety of GLP-1 receptor agonists for type 2 diabetes mellitus patients with overweight/obesity: A systematic review and network meta-analysis.

Wen Z, Sun W, Wang H, Chang R, Wang J, Song C, Zhang S, Ni Q, An X

Diabetes research and clinical practice17 Jan 2025Cited by 11 (Europe PMC)

PMID39828025DOI10.1016/j.diabres.2025.111999PepBankPUB-39828025

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

4 results from studies that gave the peptide. 4 results from people.

01HumanSystematic reviewEfficacy outcome
In adults with type 2 diabetes and overweight or obesity, tirzepatide lowered HbA1c more than placebo in a network meta-analysis (-1.64).
In plain wordsIn adults with type 2 diabetes and overweight, tirzepatide lowered HbA1c, a blood sugar marker, more than placebo in a pooled analysis.
Peptide
Tirzepatide
Outcome
DecreaseHbA1c change versus placebo
Study
n: not reported in source
Comparator
Placebo
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated
Source sentences
Summary
Tirzepatide showed superior effects in lowering blood glucose (Compared with placebo, increased glycated hemoglobin: -1.64 (-1.94, -1.35)
2 context sentences(design, population, supporting numbers)
Summary · context
We searched PubMed, Embase, Cochrane Library, and Web of Science up to December 20, 2024, for randomized controlled trials (RCTs) involving T2DM patients with overweight/obesity treated with GLP-1RAs, with the control group receiving either a placebo or another GLP-1RA.
Summary · context
A total of 4548 articles were retrieved, and 41 RCTs were included, comprising 15,126 patients and 13 different GLP-1RAs.
Report a problemFND-3982802501
02HumanSystematic reviewEfficacy outcome
In adults with type 2 diabetes and overweight or obesity, tirzepatide lowered fasting blood glucose more than placebo in a network meta-analysis (-2.10).
In plain wordsIn adults with type 2 diabetes and overweight, tirzepatide lowered fasting blood sugar more than placebo in a pooled analysis.
Peptide
Tirzepatide
Outcome
DecreaseFasting blood glucose change versus placebo
Study
n: not reported in source
Comparator
Placebo
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated
Source sentences
Summary
Tirzepatide showed superior effects in lowering blood glucose (Compared with placebo, increased glycated hemoglobin: -1.64 (-1.94, -1.35), increased fasting blood glucose: -2.10 (-2.95, -1.25))
2 context sentences(design, population, supporting numbers)
Summary · context
We searched PubMed, Embase, Cochrane Library, and Web of Science up to December 20, 2024, for randomized controlled trials (RCTs) involving T2DM patients with overweight/obesity treated with GLP-1RAs, with the control group receiving either a placebo or another GLP-1RA.
Summary · context
A total of 4548 articles were retrieved, and 41 RCTs were included, comprising 15,126 patients and 13 different GLP-1RAs.
Report a problemFND-3982802502
03HumanSystematic reviewEfficacy outcome
In adults with type 2 diabetes and overweight or obesity, tirzepatide reduced weight more than placebo in a network meta-analysis (-9.89).
In plain wordsIn adults with type 2 diabetes and overweight, tirzepatide lowered body weight more than placebo in a pooled analysis.
Peptide
Tirzepatide
Outcome
DecreaseWeight change versus placebo
Study
n: not reported in source
Comparator
Placebo
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated
Source sentences
Summary
and weight loss (Compared with placebo, increased weight: -9.89 (-11.29, -8.49)
2 context sentences(design, population, supporting numbers)
Summary · context
We searched PubMed, Embase, Cochrane Library, and Web of Science up to December 20, 2024, for randomized controlled trials (RCTs) involving T2DM patients with overweight/obesity treated with GLP-1RAs, with the control group receiving either a placebo or another GLP-1RA.
Summary · context
A total of 4548 articles were retrieved, and 41 RCTs were included, comprising 15,126 patients and 13 different GLP-1RAs.
Report a problemFND-3982802503
04HumanSystematic reviewEfficacy outcome
In adults with type 2 diabetes and overweight or obesity, tirzepatide reduced BMI more than placebo in a network meta-analysis (-3.85).
In plain wordsIn adults with type 2 diabetes and overweight, tirzepatide lowered body mass index more than placebo in a pooled analysis.
Peptide
Tirzepatide
Outcome
DecreaseBMI change versus placebo
Study
n: not reported in source
Comparator
Placebo
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated
Source sentences
Summary
and weight loss (Compared with placebo, increased weight: -9.89 (-11.29, -8.49), rincreased BMI: -3.85 (-4.71, -2.99)).
2 context sentences(design, population, supporting numbers)
Summary · context
We searched PubMed, Embase, Cochrane Library, and Web of Science up to December 20, 2024, for randomized controlled trials (RCTs) involving T2DM patients with overweight/obesity treated with GLP-1RAs, with the control group receiving either a placebo or another GLP-1RA.
Summary · context
A total of 4548 articles were retrieved, and 41 RCTs were included, comprising 15,126 patients and 13 different GLP-1RAs.
Report a problemFND-3982802504

Studies that did not test the peptide alone4

In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Tirzepatide.

05HumanNot a test of Tirzepatide aloneSystematic reviewEfficacy outcome
In adults with type 2 diabetes and overweight or obesity, clinical efficacy of GLP-1RAs as a class on lipid levels was not widely observed.
In plain wordsIn adults with type 2 diabetes and overweight, GLP-1 drugs as a group did not widely improve blood fats.
Peptide
Tirzepatide
Outcome
No significant changeLipid levels (pooled GLP-1RAs)
Study
n: not reported in source
Comparator
Placebo or another GLP-1RA
Outcome group
Lipids · Metabolic and weight
Source sentences
Summary
However, clinical efficacy of GLP-1RAs in lipid levels, blood pressure, and pancreatic function was not widely observed.
2 context sentences(design, population, supporting numbers)
Summary · context
We searched PubMed, Embase, Cochrane Library, and Web of Science up to December 20, 2024, for randomized controlled trials (RCTs) involving T2DM patients with overweight/obesity treated with GLP-1RAs, with the control group receiving either a placebo or another GLP-1RA.
Summary · context
A total of 4548 articles were retrieved, and 41 RCTs were included, comprising 15,126 patients and 13 different GLP-1RAs.
In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.
Report a problemFND-3982802505
06HumanNot a test of Tirzepatide aloneSystematic reviewEfficacy outcome
In adults with type 2 diabetes and overweight or obesity, clinical efficacy of GLP-1RAs as a class on blood pressure was not widely observed.
In plain wordsIn adults with type 2 diabetes and overweight, GLP-1 drugs as a group did not widely lower blood pressure.
Peptide
Tirzepatide
Outcome
No significant changeBlood pressure (pooled GLP-1RAs)
Study
n: not reported in source
Comparator
Placebo or another GLP-1RA
Outcome group
Blood pressure · Cardiovascular
Source sentences
Summary
However, clinical efficacy of GLP-1RAs in lipid levels, blood pressure, and pancreatic function was not widely observed.
2 context sentences(design, population, supporting numbers)
Summary · context
We searched PubMed, Embase, Cochrane Library, and Web of Science up to December 20, 2024, for randomized controlled trials (RCTs) involving T2DM patients with overweight/obesity treated with GLP-1RAs, with the control group receiving either a placebo or another GLP-1RA.
Summary · context
A total of 4548 articles were retrieved, and 41 RCTs were included, comprising 15,126 patients and 13 different GLP-1RAs.
In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.
Report a problemFND-3982802506
07HumanNot a test of Tirzepatide aloneSystematic reviewEfficacy outcome
In adults with type 2 diabetes and overweight or obesity, clinical efficacy of GLP-1RAs as a class on pancreatic function was not widely observed.
In plain wordsIn adults with type 2 diabetes and overweight, GLP-1 drugs as a group did not widely improve pancreas function.
Peptide
Tirzepatide
Outcome
No significant changePancreatic function (pooled GLP-1RAs)
Study
n: not reported in source
Comparator
Placebo or another GLP-1RA
Outcome group
Glycemic control · Metabolic and weight
Source sentences
Summary
However, clinical efficacy of GLP-1RAs in lipid levels, blood pressure, and pancreatic function was not widely observed.
2 context sentences(design, population, supporting numbers)
Summary · context
We searched PubMed, Embase, Cochrane Library, and Web of Science up to December 20, 2024, for randomized controlled trials (RCTs) involving T2DM patients with overweight/obesity treated with GLP-1RAs, with the control group receiving either a placebo or another GLP-1RA.
Summary · context
A total of 4548 articles were retrieved, and 41 RCTs were included, comprising 15,126 patients and 13 different GLP-1RAs.
In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.
Report a problemFND-3982802507
08HumanNot a test of Tirzepatide aloneSystematic reviewSafety outcome
In adults with type 2 diabetes and overweight or obesity, adverse reactions were significant with GLP-1RAs as a class but overall acceptable.
In plain wordsIn adults with type 2 diabetes and overweight, GLP-1 drugs as a group caused notable side effects that were judged acceptable overall.
Peptide
Tirzepatide
Outcome
IncreaseAdverse reactions (pooled GLP-1RAs)
Study
n: not reported in source
Comparator
Placebo or another GLP-1RA
Outcome group
Adverse events · Whole body
Source sentences
Summary
Adverse reactions were significant with GLP-1RAs, but overall acceptable.
2 context sentences(design, population, supporting numbers)
Summary · context
We searched PubMed, Embase, Cochrane Library, and Web of Science up to December 20, 2024, for randomized controlled trials (RCTs) involving T2DM patients with overweight/obesity treated with GLP-1RAs, with the control group receiving either a placebo or another GLP-1RA.
Summary · context
A total of 4548 articles were retrieved, and 41 RCTs were included, comprising 15,126 patients and 13 different GLP-1RAs.
In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.
Report a problemFND-3982802508

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 12:58 UTC
Study results updated
Version 1
9 Oct 2026, 03:07 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.